Evidence map›Paper›PMID 28903739›Full record

ArticleBMC genomics2017

Evolving DNA methylation and gene expression markers of B-cell chronic lymphocytic leukemia are present in pre-diagnostic blood samples more than 10 years prior to diagnosis.

Panagiotis Georgiadis, Irene Liampa, Dennie G Hebels, Julian Krauskopf, Aristotelis Chatziioannou, Ioannis Valavanis, Theo M C M de Kok, Jos C S Kleinjans, Ingvar A Bergdahl, Beatrice Melin and 8 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. DNA methylation alterations caused byFrontiers in cellular and infection microbiology · 2022
    Review
  4. Review
  5. Chronic Lymphocytic Leukemia.Cold Spring Harbor perspectives in medicine · 2021
    Review
  6. Methylation alteration ofOncotarget · 2019
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 4 countries.

Panagiotis GeorgiadisInstitute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48, Vassileos Constantinou Avenue, 11635, Athens, Greece.
Irene LiampaInstitute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48, Vassileos Constantinou Avenue, 11635, Athens, Greece.
Dennie G HebelsDepartment of Toxicogenomics, Maastricht University, 6229, Maastricht, ER, Netherlands.
Julian KrauskopfDepartment of Toxicogenomics, Maastricht University, 6229, Maastricht, ER, Netherlands.
Aristotelis ChatziioannouInstitute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48, Vassileos Constantinou Avenue, 11635, Athens, Greece.
Ioannis ValavanisInstitute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48, Vassileos Constantinou Avenue, 11635, Athens, Greece.
Theo M C M de KokDepartment of Toxicogenomics, Maastricht University, 6229, Maastricht, ER, Netherlands.
Jos C S KleinjansDepartment of Toxicogenomics, Maastricht University, 6229, Maastricht, ER, Netherlands.
Ingvar A BergdahlDepartment of Biobank Research, and Occupational and Environmental Medicine, Department of Public Health and Clinical Medicine, Umeå University, 901 87, Umeå, Sweden.
Beatrice MelinDepartment of Radiation Sciences, Oncology, Umeå University, 901 87, Umeå, Sweden.
Florentin SpaethDepartment of Radiation Sciences, Oncology, Umeå University, 901 87, Umeå, Sweden.
Domenico PalliThe Institute for Cancer Research and Prevention, 50141, Florence, Italy.
R C H VermeulenInstitute for Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands.
J VlaanderenInstitute for Risk Assessment Sciences, Utrecht University, Utrecht, Netherlands.
Marc Chadeau-HyamDepartment of Epidemiology and Biostatistics, MRC-HPA Centre for Environment and Health, School of Public Health, Faculty of Medicine, Imperial College, London, W2 1PG, UK.
Paolo VineisDepartment of Epidemiology and Biostatistics, MRC-HPA Centre for Environment and Health, School of Public Health, Faculty of Medicine, Imperial College, London, W2 1PG, UK.
Soterios A KyrtopoulosInstitute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48, Vassileos Constantinou Avenue, 11635, Athens, Greece. skyrt@eie.gr.
EnviroGenomarkers consortium
National Hellenic Research Foundation · GRMaastricht University · NLUmeå University · SEImperial College London · GBUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundB-cell chronic lymphocytic leukemia (CLL) is a common type of adult leukemia. It often follows an indolent course and is preceded by monoclonal B-cell lymphocytosis, an asymptomatic condition, however it is not known what causes subjects with this condition to progress to CLL. Hence the discovery of prediagnostic markers has the potential to improve the identification of subjects likely to develop CLL and may also provide insights into the pathogenesis of the disease of potential clinical relevance.

resultsWe employed peripheral blood buffy coats of 347 apparently healthy subjects, of whom 28 were diagnosed with CLL 2.0-15.7 years after enrollment, to derive for the first time genome-wide DNA methylation, as well as gene and miRNA expression, profiles associated with the risk of future disease. After adjustment for white blood cell composition, we identified 722 differentially methylated CpG sites and 15 differentially expressed genes (Bonferroni-corrected p < 0.05) as well as 2 miRNAs (FDR < 0.05) which were associated with the risk of future CLL. The majority of these signals have also been observed in clinical CLL, suggesting the presence in prediagnostic blood of CLL-like cells. Future CLL cases who, at enrollment, had a relatively low B-cell fraction (<10%), and were therefore less likely to have been suffering from undiagnosed CLL or a precursor condition, showed profiles involving smaller numbers of the same differential signals with intensities, after adjusting for B-cell content, generally smaller than those observed in the full set of cases. A similar picture was obtained when the differential profiles of cases with time-to-diagnosis above the overall median period of 7.4 years were compared with those with shorted time-to-disease. Differentially methylated genes of major functional significance include numerous genes that encode for transcription factors, especially members of the homeobox family, while differentially expressed genes include, among others, multiple genes related to WNT signaling as well as the miRNAs miR-150-5p and miR-155-5p.

conclusionsOur findings demonstrate the presence in prediagnostic blood of future CLL patients, more than 10 years before diagnosis, of CLL-like cells which evolve as preclinical disease progresses, and point to early molecular alterations with a pathogenetic potential.

Indexed as

Biomarkers, TumorGene Expression ProfilingLeukemia, Lymphocytic, Chronic, B-CellDNA MethylationGene Expression Regulation, NeoplasticHumansMicroRNAsPrognosisTime FactorsBiomarkers, TumorMicroRNAsBiomarkers of riskEpigenomicsmiRNAMolecular epidemiologyProspective cohortTranscriptomics

Identifiers

PMID28903739
PMCPMC5598006
OpenAlexW2755260711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.